All are pure beta emitters except:

D i.e. Samarium-153 Pure beta 63) emitters (radionuclides) are phosphorus-32, strontium-90, Yttrium-90 and tritium-30Q. Whereas Samarium-153 & Rhenium-186 are mixed /3 and y emittersQ. Systemic radionuclide therapy for bone metastases and pain include 89Sr, 32P, 186Rhand 153SaQ. Phosphorus-32 the first agent to be used is now rarely used b/ o risk of myelo suppression, pancytopenia & acute leukemia. Strontium-89 decays by 3 emission to yttrium-89 with a half life of 50.6 days (13 energy 1.46MeV). It is quickly taken up by mineral material of bone b/o chemical similarity to calcium and b/o extremely little y radiation patient is not a radiation hazard to family members & hospital staff. Samarium-153 is a aificial radionuclide that emits R paicles of 0.81 MeV (20%), 0.71 Mev (30%), 0.64 MeV (50%) and gamma photons of 103 KeV (28%). It has a sho half life of 46.3 hours and is chelated with EDTMP to produce bone seaking complex. Rhenium-186 emits paicles of 1.07 MeV and a 137 KeV gamma rays. It has a sho half life of 3.8 days and is chelated with HEDP to produce bone seeking complex.